Rheumatology International

, Volume 28, Issue 5, pp 503–506

Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab

  • Anke Braun
  • Thomas Neumann
  • Peter Oelzner
  • Gert Hein
  • Hermann-Josef Gröne
  • Mirjana Ziemer
  • Gunter Wolf
Case Report

Abstract

We describe the case of a 78-year-old woman with peripheral neuropathy, neurogenic muscular atrophy, skin ulcers, arthritis and immune complex glomerulonephritis. Detection of mixed cryoglobulins in combination with typical clinical symptoms, and the exclusion of hepatitis C and other underlying diseases, led to the rare diagnosis of essential cryoglobulinaemic vasculitis type III. Because initial interventions with prednisolone, plasmapheresis and cyclophosphamide pulse therapy failed to induce remission, therapy with rituximab, a chimeric monoclonal antibody that reacts specifically with the CD20 antigen, was initiated. Rituximab was administered intravenously at a dose of 375 mg/m2 body surface. After five applications, the patient showed remission of clinical symptoms and complete normalisation of laboratory values. These results suggest that rituximab is an alternative therapeutical approach with strikingly good clinical outcome in patients with cryoglobulinaemic vasculitis type III.

Keywords

Cryoglobulinaemia Type III Vasculitis Rituximab Glomerulonephritis 

References

  1. 1.
    Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M (1974) Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57:775–788PubMedCrossRefGoogle Scholar
  2. 2.
    Rieu V, Cohen P, Andre MH et al (2002) Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. Rheumatology 41:290–300PubMedCrossRefGoogle Scholar
  3. 3.
    Agnello V, Chung RT, Kaplan LM (1992) A role for hepatitis C virus infection in type 2 cryoglobulinaemia. N Engl J Med 327:1490–1495PubMedCrossRefGoogle Scholar
  4. 4.
    Ferri C, Marzo E, longbardo G (1993) Interferon alpha in mixed cryoglobulinimia patients. A randomized cross over controlled trial. Blood 81:1123–1126Google Scholar
  5. 5.
    Perek J, Mittelmann M, Eisbruch A, Djaldette M (1984) Systemic lupus erythematosus preceeded by long-term cryoglobulinaemia. Ann Rheum Dis 43:339–340PubMedCrossRefGoogle Scholar
  6. 6.
    Strunk J, Taborski U, Neeck G (2002) Essential cryoglobulinaemic vasculitis with severe peripheral neuropathy and neurogenic muscular atrophy––including remission by cascade filtration. Z Rheumatol 61:733–739PubMedCrossRefGoogle Scholar
  7. 7.
    Lamprecht P, Gause A, Gross WL (1999) Cryoglobulinaemic vasculitis (review). Arthritis Rheum 42:2507–2516PubMedCrossRefGoogle Scholar
  8. 8.
    Zaja F, de Vita S, Mazarro C, Sacco S, Damiani D, de Marchi G, Micheluti A, Baccarani M, Fanin R, Ferraccioli G (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinaemia. Blood 101:3827–3834PubMedCrossRefGoogle Scholar
  9. 9.
    Ghobrial IM, Uslan DZ, Call TG, Witzig TE, Gertz MA (2004) Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinaemia secondary to Waldenström macroglobulinemia does not indicate failure of response. Am J Hematol 77:329–30PubMedCrossRefGoogle Scholar
  10. 10.
    Lamprecht P, Lerin-Lozano C, merz H, Dennin RH, Gause A, Voswinkel J, Peters SO, Gutzeit O, Arlt AC, Solbach W, Gross WL (2003) Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 62:1230–1233PubMedCrossRefGoogle Scholar
  11. 11.
    Basse G Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, Guitard J, Lavayssiere L, Oksman F, Durand D, Rostaing L (2006) Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 38:2308–2310CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Anke Braun
    • 1
    • 2
  • Thomas Neumann
    • 2
  • Peter Oelzner
    • 2
  • Gert Hein
    • 2
  • Hermann-Josef Gröne
    • 3
  • Mirjana Ziemer
    • 4
  • Gunter Wolf
    • 2
  1. 1.University of Heidelberg, Bethanien HospitalHeidelbergGermany
  2. 2.Department of Internal Medicine III, Division of Rheumatology and OsteologyUniversity of JenaJenaGermany
  3. 3.German Cancer Research CentreHeidelbergGermany
  4. 4.Department of DermatologyUniversity of JenaJenaGermany

Personalised recommendations